Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860091 | 0.89 | ROCK2 (0.60) | IMPDH2TRPV1ROCK2PRMT3MCHR1 | |
| SCHEMBL2164137 | 0.82 | PRMT3 (0.69) | IMPDH2ROCK2PRMT3MAPTHTT | |
| SCHEMBL19860082 | 0.80 | ROCK1 (0.60) | IMPDH2ROCK2PRMT3MCHR1 | |
| SCHEMBL3566775 | 0.80 | PRMT3 (0.72) | IMPDH2ROCK2PRMT3MAPTHTT | |
| SCHEMBL14124401 | 0.79 | IMPDH2 (0.61) | IMPDH2ROCK2PRMT3MEN1MAPT | |
| SCHEMBL19860107 | 0.78 | ROCK2 (0.57) | IMPDH2TRPV1ROCK2PRMT3MEN1 | |
| SCHEMBL3174300 | 0.78 | KDR (0.70) | BRAFKDRMAPK14TNNI3KTRPV1 | |
| SCHEMBL28279154 | 0.77 | MAPT (0.73) | MEN1MAPTHTTRAB9AKMT2A | |
| SCHEMBL5658162 | 0.76 | IMPDH2 (0.73) | IMPDH2TRPV1ROCK2PRMT3 | |
| SCHEMBL12059419 | 0.76 | MAPT (0.61) | BRAFKDRMAPK14TNNI3KNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899714-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2016-09-29 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2118064-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280656-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
| US-10899714-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885BRAF 269/4885KDR 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.